These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38592331)

  • 21. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.
    Ahmetlic F; Fauser J; Riedel T; Bauer V; Flessner C; Hömberg N; Hennel R; Brenner E; Lauber K; Röcken M; Mocikat R
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33441389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
    Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
    Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.
    Dietsch GN; Lu H; Yang Y; Morishima C; Chow LQ; Disis ML; Hershberg RM
    PLoS One; 2016; 11(2):e0148764. PubMed ID: 26928328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis.
    Bresnihan B; Roux-Lombard P; Murphy E; Kane D; FitzGerald O; Dayer JM
    Ann Rheum Dis; 2002 Aug; 61(8):726-9. PubMed ID: 12117681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
    Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
    Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
    PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polysaccharide from
    Park HB; Hwang J; Zhang W; Go S; Kim J; Choi I; You S; Jin JO
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33302530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
    Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
    Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.
    Nath PR; Pal-Nath D; Mandal A; Cam MC; Schwartz AL; Roberts DD
    Cancer Immunol Res; 2019 Sep; 7(9):1547-1561. PubMed ID: 31362997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
    Dong W; Wu X; Ma S; Wang Y; Nalin AP; Zhu Z; Zhang J; Benson DM; He K; Caligiuri MA; Yu J
    Cancer Discov; 2019 Oct; 9(10):1422-1437. PubMed ID: 31340937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade
    Ghosh S; Sharma G; Travers J; Kumar S; Choi J; Jun HT; Kehry M; Ramaswamy S; Jenkins D
    Mol Cancer Ther; 2019 Mar; 18(3):632-641. PubMed ID: 30587557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.